Pharmaceutical Supply Chain & Healthcare Advisory
Specialist advisory for pharmaceutical manufacturers, healthcare distributors, governments and development organisations navigating Africa's complex and critical healthcare supply landscape.
Healthcare Supply Chain Integrity Across Africa's Most Demanding Markets
Africa's pharmaceutical and healthcare sector stands at a critical inflection point. The continent accounts for approximately 25% of the global disease burden yet produces less than 2% of its medicines domestically — a structural dependency that the COVID-19 pandemic exposed with devastating clarity. Governments, international health organisations and the private sector are now investing significantly in expanding African pharmaceutical manufacturing capacity, strengthening supply chains and improving healthcare access across the continent's 54 nations. For pharmaceutical companies, healthcare distributors, logistics providers and investors, this transformation creates extraordinary commercial opportunity alongside complex operational challenges.
Lycia Limited's Pharmaceutical and Healthcare Advisory practice provides specialist support to organisations operating across every dimension of Africa's healthcare supply ecosystem. We advise pharmaceutical manufacturers on regulatory strategy and market access, support distributors in navigating complex multi-country operations, assist governments and procurement agencies in strengthening their supply chain frameworks, and guide investors evaluating Africa's rapidly growing pharmaceutical market.
Our practice is distinguished by our deep understanding of African regulatory environments, our relationships with national medicines regulatory authorities across 16 jurisdictions, and our experience in navigating the intersection of commercial interests and public health obligations that characterises pharmaceutical advisory in developing markets.
At a Glance
The African Pharmaceutical Landscape: A Sector in Transformation
Africa's pharmaceutical market is one of the fastest-growing in the world, driven by population growth, rising incomes, expanding health insurance coverage and increased government healthcare expenditure. McKinsey & Company estimates that the continent's pharmaceutical market could reach $70 billion by 2030, with sub-Saharan Africa alone growing at compound annual rates of 8–12% in key markets. The African Medicines Agency, now becoming operational, promises to harmonise regulatory frameworks across the continent — reducing the fragmentation that currently makes pan-African market access so costly and complex.
Yet operating in Africa's pharmaceutical sector requires navigating challenges that do not exist in comparable scale elsewhere. Regulatory frameworks vary enormously between jurisdictions — from the relatively sophisticated NAFDAC system in Nigeria and SAHPRA in South Africa to nascent regulatory bodies in smaller markets. Counterfeit medicine prevalence remains a significant concern in many markets, with WHO estimates suggesting that up to 30% of medicines in some sub-Saharan markets are substandard or falsified. Cold chain infrastructure is often inadequate, particularly for biologics and vaccines. Customs and import procedures can be opaque, slow and subject to facilitation risks. And procurement systems — whether public or private — frequently lack the governance frameworks and financing mechanisms that international suppliers require.
Lycia Limited has built its pharmaceutical advisory practice around an intimate understanding of these realities. We work with international pharmaceutical companies seeking market access, with African distributors seeking to strengthen their operations and compliance frameworks, with governments and procurement agencies seeking to improve supply chain governance, and with investors evaluating the growing number of pharmaceutical manufacturing opportunities emerging across the continent.
Our geographic coverage includes all major African pharmaceutical markets — South Africa, Nigeria, Kenya, Ghana, Ethiopia, Tanzania, Egypt, Morocco, Côte d'Ivoire, Senegal, Rwanda and Zambia — as well as the regional economic blocs that are increasingly shaping market access strategy: ECOWAS, the East African Community, SADC and the Common Market for Eastern and Southern Africa.
Pharmaceutical & Healthcare Advisory Services
Our pharmaceutical practice addresses every dimension of market access, supply chain integrity, regulatory compliance and commercial development across African healthcare markets.
Regulatory Strategy & Market Access
Advisory on regulatory requirements, dossier preparation, submission strategy and approval timelines for pharmaceutical products seeking registration across African national medicines authorities — including SAHPRA, NAFDAC, PPB, TFDA, and other national regulators.
Distributor Identification & Due Diligence
Systematic identification and independent due diligence of pharmaceutical distributors, wholesalers and healthcare logistics providers across African markets — assessing regulatory compliance, cold chain capability, financial standing and market coverage.
Supply Chain Integrity & Anti-Counterfeiting
Advisory on supply chain integrity frameworks, track-and-trace systems, anti-counterfeiting technology and serialisation compliance — protecting product integrity and regulatory standing in markets with significant counterfeiting risk.
Government & Public Health Procurement
Support for pharmaceutical suppliers navigating government and public health procurement processes, including WHO prequalification, PEPFAR supply programmes, Global Fund procurement, UNICEF supply division tendering and national essential medicines list inclusion.
Cold Chain & Logistics Advisory
Specialist advisory on temperature-controlled supply chain requirements for biologics, vaccines and cold-chain-dependent pharmaceuticals across African markets — including cold storage infrastructure assessment, last-mile delivery solutions and regulatory compliance.
Manufacturing Investment Advisory
Advisory for investors and pharmaceutical companies evaluating African manufacturing investments — including site selection, regulatory requirements for local manufacturing, partnership structuring, technology transfer arrangements and financing.
Licensing & Technology Transfer
Support for international pharmaceutical companies seeking to license products or transfer technology to African manufacturing partners — including partner identification, due diligence, licensing agreement structuring and regulatory implications.
Healthcare Investor Advisory
Commercial and operational due diligence for investors evaluating African pharmaceutical and healthcare assets — from retail pharmacy chains and diagnostic networks to manufacturing facilities and healthcare logistics companies.
Pharmaceutical & Healthcare Client Profiles
Lycia's pharmaceutical practice serves a wide range of organisations across the healthcare supply chain, from international manufacturers to local distributors and public sector procurement agencies.
International Pharmaceutical Manufacturers
Multinational and mid-tier pharmaceutical manufacturers seeking market access across African jurisdictions — requiring regulatory strategy, distributor identification and commercial market entry support.
Generic Medicine Producers
Generic and biosimilar manufacturers, particularly from India and China, seeking to formalise and strengthen their African distribution arrangements — improving regulatory compliance and supply chain governance.
African Healthcare Distributors
Pan-African and national pharmaceutical distributors seeking to improve their regulatory compliance, cold chain capability, operational efficiency and access to international product portfolios.
Government Health Ministries
Ministries of health and national procurement agencies seeking to strengthen pharmaceutical supply chain frameworks, improve procurement governance and ensure reliable access to essential medicines at affordable prices.
Development Finance & Health Investors
Impact investors, development finance institutions and healthcare private equity funds evaluating investments in African pharmaceutical manufacturing, distribution and retail healthcare businesses.
International Health Organisations
WHO, UNICEF, PEPFAR implementing partners and other international health organisations requiring local advisory support for pharmaceutical supply chain programmes and health systems strengthening interventions.
Where We Operate
Lycia Limited maintains active advisory relationships, market intelligence networks and on-the-ground expertise across the following markets.
The Lycia Pharmaceutical Advisory Advantage
Regulatory Depth Across Multiple Jurisdictions
Unlike advisors with expertise in only one or two markets, Lycia maintains active advisory relationships across 16 African pharmaceutical regulatory environments — enabling us to support pan-African market access strategies with genuine jurisdictional specificity.
Public and Private Sector Fluency
African pharmaceutical markets are characterised by a complex interplay between public procurement systems and private market channels. Our fluency in both dimensions — and in the interface between them — provides a distinctive advisory advantage.
Supply Chain Integrity Focus
In markets where counterfeit medicines pose genuine public health risks, supply chain integrity is not a compliance nicety but a commercial and ethical imperative. Our integrity-first approach to distributor assessment and supply chain design protects both patients and our clients' regulatory standing.
Manufacturing Transformation Knowledge
As African pharmaceutical manufacturing capacity grows — driven by the African Union's Pharmaceutical Manufacturing Plan for Africa and significant government and DFI investment — we are positioned to advise on the investment, licensing and operational dimensions of this transformation.
Development Partner Network
Our relationships with international development organisations — including WHO, UNICEF, PEPFAR implementing partners and development finance institutions — enables us to help commercial clients align with the public health programmes that represent the largest procurement volumes in many African markets.
Ethical Commercial Practice
Pharmaceutical advisory in developing markets carries unique ethical dimensions. Lycia maintains a strict code of practice governing all healthcare sector engagements, ensuring that our commercial advice is always compatible with the primacy of public health outcomes.
Pharmaceutical Advisory Engagement Examples
The following illustrative examples reflect the nature and scope of engagements Lycia Limited undertakes. Client confidentiality is maintained at all times.
Regional Market Access Strategy
Engaged by a European generic medicine manufacturer to develop a regional market access strategy for East Africa, including regulatory submission planning across three jurisdictions, distributor identification and commercial terms negotiation.
Pharmaceutical Distribution Due Diligence
Retained by an Asian pharmaceutical company to conduct independent due diligence on potential distribution partners in Nigeria — the continent's largest pharmaceutical market — covering NAFDAC compliance, cold chain capability and financial standing.
Essential Medicines Procurement Advisory
Commissioned by a government health ministry to review and reform its essential medicines procurement process, addressing supply chain vulnerabilities and improving alignment with WHO procurement standards to access preferential pricing programmes.
Lycia Limited provides advisory services to the pharmaceutical and healthcare sector. All advisory is provided in accordance with applicable pharmaceutical regulations, anti-bribery legislation including the UK Bribery Act 2010, and healthcare industry codes of conduct. Lycia Limited does not provide medical advice, clinical recommendations or regulatory submissions on behalf of clients. Clients are responsible for ensuring that all products and operations meet applicable regulatory requirements in relevant jurisdictions. All pharmaceutical advisory engagements are subject to enhanced compliance screening.
Ready to Unlock Opportunities?
Connect with Lycia to explore how we can support your goals across Africa and beyond.